ArticleJournal of family medicine and primary care2025
Comparative analysis of tuberculosis drug consumption data in public and private sectors across selected districts of Madhya Pradesh.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to compare drug consumption rates in public and private healthcare sectors between 2018 and 2022 in the Tikamgarh, Datia, and Niwari districts of Madhya Pradesh. Design: A community-based survey methodology was employed, alongside an analysis of program data and evaluation of anti-TB drug sales and utilization from both healthcare sectors. Materials and Methods: Data were collected from district hospitals in both the public and private sectors. Hospital records and pharmacy logs were reviewed to assess anti-TB medication consumption rates from 2018 to 2022. Sputum samples from patients with chest symptoms or a history of anti-TB treatment were tested using Xpert/Rif/TrueNat. The analysis compared drug consumption rates based on hospital records and calculated according to pharmacy sales data. Results: The mean patient months in the public sector (10,354 months, SD = 8,780) significantly exceeded those in the private sector (4,820 months, SD = 9,519). Public sector drug sales varied, with Tikamgarh declining sharply from 38,304 patient months in 2018 to 8,810 in 2019, while Datia remained more stable. The private sector, particularly in Datia, peaked at 30,238 patient months in 2020. One-way ANOVA showed no significant differences between sectors for patient months ( Conclusion: Aligning drug consumption patterns across healthcare sectors is vital for effective tuberculosis management. Addressing disparities in drug consumption rates is crucial for accurate TB incidence estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.